Schizophrenia Clinical Trials in Worcester, Massachusetts

5 studies are recruiting for schizophrenia in Worcester, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Local Institution - 0059, Worcester, Massachusetts

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

2. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   University of Massachusetts Chan Medical School, Worcester, Massachusetts

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

3. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0059, Worcester, Massachusetts

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

4. Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

   The main question this study is trying to answer is whether lumateperone, an FDA-approved antipsychotic drug, can help reduce possible side effects of clozapine, such as weight gain and elevated levels of sugar and bad cholesterol. Participants will be randomly assigned to either take lumateperone …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   UMass Chan Medical School, Worcester, Massachusetts

   Run by

   University of Massachusetts, Worcester

   See if you can join NCT06174116 on ClinicalTrials.gov

5. Enhanced Coordinated Specialty Care for Early Psychosis

   The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatm…

   Stage

   Not phased

   Ages

   Any age

   Site

   UMass Memorial Community Healthlink STEP Clinic, Worcester, Massachusetts

   Locations

   5 in total

   Run by

   Mclean Hospital

   See if you can join NCT06071858 on ClinicalTrials.gov